Livzon Pharmaceutical Group Inc. (01513.HK, 000513.SZ) Releases November 2025 Monthly Return

Bulletin Express

2025/12/01

Livzon Pharmaceutical Group Inc. published its Monthly Return on Movements in Securities for November 2025. The authorized share capital stood at RMB 904,100,430, comprising 299,807,117 H shares and 604,293,313 A shares. The total number of issued H shares remained at 299,807,117, while the total number of issued A shares stayed at 604,293,313.

According to the announcement, 16,193,259 A shares repurchased on 24 December 2024 have not yet been cancelled as of the end of November 2025. No movements were reported regarding share options, warrants, or convertible securities. The company confirmed that all applicable listing rules and regulatory requirements have been met for the reported period.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1189636358"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1189636358\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1189636358?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-01 17:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189636358","market":"us","top_or_hot":-1,"title":"Livzon Pharmaceutical Group Inc. (01513.HK, 000513.SZ) Releases November 2025 Monthly Return","media":"Bulletin Express","content":"<p>Livzon Pharmaceutical Group Inc. published its Monthly Return on Movements in Securities for November 2025. The authorized share capital stood at RMB 904,100,430, comprising 299,807,117 H shares and 604,293,313 A shares. The total number of issued H shares remained at 299,807,117, while the total number of issued A shares stayed at 604,293,313.</p>\n<p>According to the announcement, 16,193,259 A shares repurchased on 24 December 2024 have not yet been cancelled as of the end of November 2025. No movements were reported regarding share options, warrants, or convertible securities. The company confirmed that all applicable listing rules and regulatory requirements have been met for the reported period.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Livzon Pharmaceutical Group Inc. (01513.HK, 000513.SZ) Releases November 2025 Monthly Return</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLivzon Pharmaceutical Group Inc. (01513.HK, 000513.SZ) Releases November 2025 Monthly Return\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2025-12-01 17:06</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Livzon Pharmaceutical Group Inc. published its Monthly Return on Movements in Securities for November 2025. The authorized share capital stood at RMB 904,100,430, comprising 299,807,117 H shares and 604,293,313 A shares. The total number of issued H shares remained at 299,807,117, while the total number of issued A shares stayed at 604,293,313.</p>\n<p>According to the announcement, 16,193,259 A shares repurchased on 24 December 2024 have not yet been cancelled as of the end of November 2025. No movements were reported regarding share options, warrants, or convertible securities. The company confirmed that all applicable listing rules and regulatory requirements have been met for the reported period.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01513","symbol_name":"麗珠醫藥","start_time":0,"source_url":"","article_id":"1189636358","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1189636358","pubTimestamp":1764579986,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Livzon Pharmaceutical Group Inc. published its Monthly Return on Movements in Securities for November 2025. The authorized share capital stood at RMB 904,100,430, comprising 299,807,117 H shares and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01513":"丽珠医药"},"translate_title":"丽珠医药集团股份有限公司(01513.HK, 000513.SZ)发布2025年11月月报表","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01513":1},"content_text":"Livzon Pharmaceutical Group Inc. published its Monthly Return on Movements in Securities for November 2025. The authorized share capital stood at RMB 904,100,430, comprising 299,807,117 H shares and 604,293,313 A shares. The total number of issued H shares remained at 299,807,117, while the total number of issued A shares stayed at 604,293,313.\nAccording to the announcement, 16,193,259 A shares repurchased on 24 December 2024 have not yet been cancelled as of the end of November 2025. No movements were reported regarding share options, warrants, or convertible securities. The company confirmed that all applicable listing rules and regulatory requirements have been met for the reported period.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}